CA -- Biotechnology company Kythera Biopharmaceuticals, Inc. has announced that it has received $40 million in its
third round of funding from a syndicate of venture capital firms.
Kythera is using the tools of biotechnology to develop
prescription therapeutics for the emerging markets of aesthetic and restorative
dermatology for aging populations.
Jafco Ventures America led the round, which
included BBT Fund, Apothecary Capital, Versant Ventures, Arch Venture Partners,
Prospect Venture Partners, Altitude Capital Partners and WS Investment. The company said it would use the proceeds of
this financing to complete Phase II trials for its lead product ATX-101.